Therapeutic Asset Ratings

Solvatinib

Spedox-6

S^3.15,S^3.22,S^3.29-[(1,3,5-triazinane-1,3,5-triyl)tris(3-oxopropane-3,1-diyl)]{N-[5-oxo-5-({L-valyl-N⁵-carbamoyl-L-ornithyl[(4-aminophenyl)methoxy]carbonyl-N-methyl-L-valyl-Lvalyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(2R,3R)-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-3-methoxy-2-methyl-3-[(2S)-pyrrolidin-2-yl]propanamide}-N2.1-yl)pentanoyl]-?-alanyldecakis(N-methylglycyl)-L-alanyl-N6-carbamimidoyl-L-lysyl-L-?-aspartyl-L-cysteinyl-(4R)-4-hydroxy-L-prolyl-L-leucyl-L-valyl-L-asparaginyl-L-prolyl-L-leucyl-L-cysteinyl-L-leucyl-L-histidyl-L-prolyl-D-?-aspartyl-L-tryptophyl-N6-carbamimidoyl-L-lysyl-Lcysteinamide}

t3011

Tak-853

tc-510

T-Dxd

tng348

Torvutatug Samrotecan

Trop2-Car-Nk

tt-10

tt-4

Tub-040

Vofatamab

xnw27011

xnw28012

XS-02

XYA02

Capivasertib

Cdx-585

Cnsi-Fe

Cue-102

Enoblituzumab

Kand145

MIRVETUXIMAB